How to Lower DHT in Adult Males
If you need to lower DHT levels, use a 5-alpha-reductase inhibitor: either finasteride 5 mg daily (which reduces serum DHT by approximately 70%) or dutasteride 0.5 mg daily (which reduces serum DHT by 94-98%). 1
Understanding DHT and When Lowering It Is Appropriate
DHT is the most potent androgen, formed when testosterone is converted by the enzyme 5-alpha-reductase. The primary medical indication for lowering DHT is benign prostatic hyperplasia (BPH), where DHT drives pathologic prostate growth 2. DHT reduction is also FDA-approved for male pattern baldness (androgenetic alopecia) at lower doses.
Critical Caveat About Lowering DHT
You should not lower DHT without a clear medical indication. DHT plays important physiological roles, and reducing it has significant consequences:
- Sexual side effects occur commonly: decreased libido, erectile dysfunction, decreased ejaculate volume, and gynecomastia 3
- Metabolic effects include potential fat accumulation in the liver (NAFLD risk), increased glucose synthesis, and reduced glucose disposal 4
- These effects can persist even after stopping the medication in some patients (post-finasteride syndrome) 5
Pharmacologic Options for Lowering DHT
Finasteride (Type 2 5α-Reductase Inhibitor)
Dosing:
- For BPH: 5 mg daily reduces serum DHT by ~70% 1, 6
- For hair loss: 1 mg daily reduces serum DHT by ~72% 6
- Doses as low as 0.2 mg daily can maximally decrease scalp DHT 6
Key characteristics:
- Selectively inhibits type 2 isoenzyme only 5
- Takes 6-12 months for full clinical effect on prostate symptoms 5
- Reduces PSA levels by approximately 50% after 1 year (must double PSA values when screening for prostate cancer) 5
Dutasteride (Dual Type 1 and Type 2 5α-Reductase Inhibitor)
Dosing:
- 0.5 mg daily reduces serum DHT by 94-98% 1
Key characteristics:
- More potent and consistent DHT suppression than finasteride 1
- Inhibits both type 1 and type 2 isoenzymes 5
- In BPH tissue (where type 2 predominates), reduces DHT by ~94% vs ~80% with finasteride 5
- Similar adverse effect profile to finasteride 1
Monitoring and Safety Considerations
Before starting treatment:
- Document baseline PSA and perform digital rectal exam 5
- Counsel patient extensively about sexual side effects
- Ensure patient understands slow onset of action (6-12 months for BPH symptoms) 5
During treatment:
- Monitor for sexual dysfunction (erectile dysfunction, decreased libido, ejaculatory dysfunction) 3
- Watch for gynecomastia 3
- Adjust PSA interpretation: After 1 year on 5α-reductase inhibitors, double the measured PSA value to assess true prostate cancer risk 5
- Consider urologic referral if PSA increases >1.4 ng/mL in any 12-month period 5
Important Clinical Context
DHT has beneficial physiological roles that are often overlooked:
- Recent evidence suggests age-related decreases in DHT correlate with impaired vascular function, increased arterial stiffness, and worsened endothelial function 7
- DHT may play adaptive roles during high-intensity exercise 8
- Elevated circulating DHT levels have NOT been associated with increased prostate cancer risk or cardiovascular disease 9
When DHT Lowering Is NOT Appropriate
Do not use 5α-reductase inhibitors in:
- Men seeking fertility (these drugs can affect reproductive function) 10
- Men without clear BPH symptoms or androgenetic alopecia
- Men with active depression or significant sexual dysfunction at baseline
- Eugonadal men without specific pathology 10
Alternative Approaches for BPH (If Avoiding DHT Reduction)
If the goal is managing BPH symptoms without lowering DHT:
- Alpha-blockers (tamsulosin, alfuzosin) provide faster symptom relief without affecting DHT 5
- Combination therapy (alpha-blocker + 5α-reductase inhibitor) is most effective for large prostates (>30cc) 5
The decision to lower DHT should be made only when there is clear pathology (BPH with prostate >30cc or PSA >1.5 ng/mL, or androgenetic alopecia) and after thorough discussion of sexual and metabolic side effects. 5, 4